MedPacto Signs Investigator-Initiated Clinical Trial Agreement with National Cancer Center for Gastric Cancer Combination Therapy

Clinical Trial of Baektoseotip + Empliciti Combination for Gastric Cancer Treatment

MedPacto.

[Asia Economy Reporter Lee Gwan-joo] MedPacto announced on the 11th that it has signed a researcher-initiated clinical trial contract with the National Cancer Center for a combination therapy of Betosertib and an immune checkpoint inhibitor in patients with recurrent gastric cancer.

This clinical trial is a researcher-initiated Phase 2 study led by Professor Kim Hak-gyun of the Gastric Cancer Center at the National Cancer Center. The research team plans to evaluate the efficacy of the combination therapy by administering Betosertib and AstraZeneca's immune checkpoint inhibitor Imfinzi (active ingredient: durvalumab) to 55 patients with metastatic or recurrent gastric cancer who have undergone three or more lines of chemotherapy.

Imfinzi is an immune checkpoint inhibitor from AstraZeneca that works by inhibiting the protein PD-L1, which helps tumor cells evade immune detection by disguising themselves as normal cells. In this clinical trial, MedPacto will supply Betosertib, and AstraZeneca will provide Imfinzi.

MedPacto is currently conducting a Phase 2a clinical trial on the combination of Betosertib and paclitaxel for gastric cancer. This combination therapy received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in October 2020.

A MedPacto representative stated, "Currently, gastric cancer is an area where the objective response rate to immune checkpoint inhibitors is significantly low, and additional treatment options are needed. Since the combination therapy of Betosertib and immune checkpoint inhibitors has already demonstrated excellent efficacy at numerous global conferences, we expect new medical outcomes to be derived from this clinical trial as well."

MedPacto is conducting clinical trials on combination therapies of Betosertib with existing anticancer drugs in multiple cancer types, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and gastric cancer.

This content was produced with the assistance of AI translation services.